Formulation Development
Aldevron Announces Expansion of mRNA Production Capability
Aldevron recently announced it will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from…
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha & Anti-PD-L1 Therapy
Immutep Limited recently announced it has received regulatory approval from the Paul-Ehrlich-Institut (PEI), German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated,…
Biomea Fusion Announces FDA Clearance of INDA for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
Biomea Fusion, Inc. recently announced the US FDA has cleared the company's Investigational New Drug (IND) application to begin a Phase 1 trial (COVALENT-103) of…
Soligenix Enters Exclusive Option Agreement With Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
Soligenix, Inc. recently announced it has entered into an exclusive option agreement with Silk Road Therapeutics granting the company the right to acquire a novel…
Combangio Awarded $15 Million to Support Ongoing KPI-012 Program for the Treatment of PCED
Kala Pharmaceuticals, Inc. recently announced the California Institute for Regenerative Medicine (CIRM) has awarded Combangio, Inc., a wholly owned subsidiary of Kala, a $15-million grant…
Tavros Therapeutics & OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform, partnership streamlines drug development for novel cancer therapies….
Aptamers Market is Expected to Reach $342 million
The aptamers industry has been growing steadily in recent years, and is expected to continue to do so in the near future. This can be…
BullFrog AI Partners With the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
BullFrog AI Holdings, Inc. recently announced a strategic partnership with the Sage Group, a leader in the provision of strategic and transactional advice to healthcare and…
Plasticell & LambdaGen Form Collaboration to Develop iPSC-Derived CAR-NK Allogeneic Cancer Immunotherapies
Plasticell Ltd recently announced today it has entered into a strategic collaboration with Singapore-based LambdaGen. Together, the two companies will exploit genome-editing technologies based on…
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown & Long Duration of Effect
Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses….
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
Vaccinex, Inc. recently announced it has completed enrollment goal in the SIGNAL-AD clinical trial for people with mild dementia due to Alzheimer’s Disease (NCT04381468). Topline…
Radiant Biotherapeutics Emerges From Stealth Mode With $8-Million Seed Round & Two Pharma Partnerships
Radiant Biotherapeutics emerged from stealth mode unveiling an $8-million seed financing and two significant pharmaceutical partnerships. The company, based on foundational IP from….
Artelo Biosciences Initiates Phase 2a Portion of its CAReS Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia & Weight Loss
Artelo Biosciences, Inc. recently announced it has initiated the Phase 2a portion of its Cancer Appetite Recovery Study (CAReS), evaluating ART27.13 for the treatment of cancer-related anorexia…
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
Avidity Biosciences, Inc. recently announced the US FDA has granted Fast Track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy (DMD) in…
Medigene AG Presents Final Phase 1 Data of TCR-T Cell Therapy in Patients With High-Risk Blood Cancers
Medigene AG recently reported final Phase 1 dose escalation results from first-in-human Study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell (TCR-T) therapy (MDG1011)…
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia
NewAmsterdam Pharma Company N.V. announced the completion of patient enrollment in the pivotal Phase 3 BROOKYLN clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia….
Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection With Transition Into Commercial-Stage Biotechnology Company
Blue Water Vaccines Inc. recently announced it has changed its corporate name to Blue Water Biotech, Inc. The corporate name change follows the company’s recent…
Aevitas Therapeutics Announces Asset Purchase Agreement With 4D Molecular Therapeutics
Aevitas Therapeutics, Inc. and 4D Molecular Therapeutics recently announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its…
Merck Strengthens Immunology Pipeline With Acquisition of Prometheus Biosciences
Merck and Prometheus Biosciences, Inc. recently announced the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for….
Clearmind Medicine Engages Experienced CRO to Support its First-in-Human Clinical Trial
Clearmind Medicine Inc. recently announced additional preparations to facilitate the commencement of the company’s clinical trial and engaged a contract research organization (CRO) to provide support for….
